Leerink analyst David Risinger notes that Bristol Myers (BMY) announced that it will enroll additional patients in the ADEPT-2 study. The firm views it as positive news that the Data Monitoring Committee recommended enrolling additional patients in Cobenfy’s ADEPT-2 trial in Alzheimer’s disease psychosis patients. Recall that the company disclosed in early August that it was scrutinizing Cobenfy trial conduct, and Leerink and consensus feared the trial could fail. The firm keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
- Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues
- Bristol Myers ADEPT-2 update an ‘incremental positive,’ says JPMorgan
- Bristol study delay could indicate positive trends, says William Blair
- Early notable gainers among liquid option names on December 3rd